
Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring …

Fresenius, Europe’s largest publicly traded healthcare provider, has engaged in discussions with Akorn, a pharmaceutical generics drugmaker, with a view …

Pfizer has bolstered its generics portfolio, paying around $63 million for 22 drugs. The company will buy 16 Abbreviated New …


